"The Aortic Aneurysm Market was valued at $ 5.47 billion in 2025 and is projected to reach $ 11.90 billion by 2034, growing at a CAGR of 10.21%."
The aortic aneurysm market encompasses the prevention, diagnosis, monitoring, and treatment ecosystem for abnormal dilation of the aorta, primarily abdominal aortic aneurysm and thoracic aortic aneurysm, where rupture risk drives high clinical urgency. The market spans screening and imaging modalities such as ultrasound, CT angiography, and MRI; medical management focused on blood pressure and risk-factor control; and interventional and surgical treatment options including endovascular aneurysm repair (EVAR), thoracic endovascular aneurysm repair (TEVAR), fenestrated and branched endografts for complex anatomy, and open surgical repair for select cases. Core end users include hospitals with vascular surgery and interventional radiology departments, cardiac surgery centers, and ambulatory centers for follow-up imaging, while key decision-makers include vascular surgeons, interventionalists, cardiologists, and primary care providers who influence screening and referral. Demand is driven by aging populations, hypertension and smoking-related risk, and increased incidental detection through imaging performed for other conditions. Outcomes depend heavily on timely diagnosis, surveillance adherence for small aneurysms, and procedural selection based on anatomy, rupture risk, and comorbidity profile.
Market momentum is shaped by continued shift toward minimally invasive endovascular approaches, device innovation that expands treatable anatomies, and improved perioperative pathways that reduce complications and length of stay. Latest trends include broader adoption of fenestrated and branched endografts for complex aneurysms, refined imaging and 3D planning to improve sizing and sealing, and increased use of intraoperative guidance technologies to reduce radiation exposure and contrast burden. Many providers are strengthening long-term surveillance programs due to the need for follow-up after EVAR/TEVAR, creating demand for imaging workflows and patient monitoring solutions. Competitive dynamics include major endovascular device manufacturers, imaging and navigation technology vendors, and specialized surgical centers; differentiation increasingly rests on device performance, anatomical versatility, ease of deployment, evidence base, and post-procedure outcomes such as reduced reintervention. Looking ahead, growth will be supported by screening efforts in at-risk populations, expansion of endovascular options for challenging anatomy, and improved patient selection and surveillance strategies that optimize long-term durability while reducing lifetime complication burden.
Aging and cardiovascular risk burden sustain demand growth Aortic aneurysm incidence rises with age and is strongly linked to smoking, hypertension, and atherosclerosis. Current detection is increasing through incidental imaging and risk-based screening. Future demand will grow as populations age and chronic disease prevalence increases. Prevention and surveillance will remain core pathways.
EVAR and TEVAR remain the dominant procedural trend Minimally invasive repair continues to replace open surgery for many suitable patients. Current preference is driven by reduced perioperative morbidity and faster recovery. Future growth depends on extending endovascular eligibility to complex anatomies. Open repair remains essential for select anatomy and long-term durability needs.
Complex anatomy solutions are expanding the addressable patient pool Fenestrated and branched endografts enable treatment of juxtarenal and thoracoabdominal aneurysms that were historically challenging. Current adoption is growing in high-volume centers with planning expertise. Future expansion will be supported by better device availability, improved planning tools, and training. This segment is high value due to procedure complexity.
Imaging, sizing, and preoperative planning are critical differentiators Outcomes depend on accurate assessment of landing zones, vessel tortuosity, and branch alignment. Current workflows increasingly use advanced CT protocols and 3D planning software. Future improvements will reduce endoleak and reintervention risk through better personalization. Imaging integration and planning efficiency influence provider preference.
Long-term surveillance is a structural requirement that shapes care models Post-EVAR/TEVAR follow-up is essential to detect endoleaks, migration, and sac expansion. Current programs emphasize imaging schedules and patient adherence. Future solutions will focus on smarter surveillance pathways, lower-radiation monitoring, and better patient engagement. Surveillance drives ongoing imaging utilization and clinic activity.
Procedure safety and durability metrics drive device competition Device makers compete on sealing performance, low endoleak rates, deliverability, and long-term durability. Current evidence and registry data strongly influence adoption in leading centers. Future competition will emphasize reduced reintervention, better compatibility with challenging anatomy, and easier deployment. Clinical outcomes remain the key purchasing driver.
Screening and referral pathways influence diagnosis stage and treatable volume Many aneurysms are asymptomatic until advanced. Current screening programs improve early detection in high-risk groups. Future growth depends on strengthening primary care referral, ultrasound access, and population health outreach. Earlier detection increases surveillance volumes and elective repair planning.
Hospital capability and specialist availability shape regional adoption EVAR/TEVAR requires trained teams, imaging infrastructure, and postoperative monitoring. Current market growth is concentrated in centers with vascular expertise and cath/OR capability. Future expansion will depend on training, center accreditation, and standardization of protocols. Volume-outcome relationships favor specialized centers.
Cost, reimbursement, and device pricing influence procedure mix Endovascular devices are resource-intensive and reimbursement policies shape adoption and device selection. Current providers balance cost with reduced length of stay and complication avoidance. Future reimbursement may increasingly reward outcomes and durability. Health economics evidence will influence procurement decisions.
Emerging guidance and navigation technologies support precision and efficiency Intraoperative imaging, fusion guidance, and advanced navigation help reduce contrast use and radiation while improving accuracy. Current adoption is rising in complex cases and high-volume centers. Future integration with robotics and improved imaging workflows can enhance consistency. Technology-enabled precision will support better outcomes and broader adoption.
| Parameter | Aortic Aneurysm Market Detail |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Market Size-Units | USD billion |
| Market Splits Covered | By Product Type, By Application, By End User, By Technology, By Distribution Channel |
| Countries Covered | North America (USA, Canada, Mexico) |
| Analysis Covered | Latest Trends, Driving Factors, Challenges, Trade Analysis, Price Analysis, Supply-Chain Analysis, Competitive Landscape, Company Strategies |
| Customization | 10% free customization (up to 10 analyst hours) to modify segments, geographies, and companies analyzed |
| Post-Sale Support | 4 analyst hours, available up to 4 weeks |
| Delivery Format | The Latest Updated PDF and Excel Data file |
By Product Type
- Stent Grafts
- Endovascular Aneurysm Repair Devices
- Surgical Clamps
By Application
- Thoracic Aneurysm
- Abdominal Aneurysm
By End User
- Hospitals
- Ambulatory Surgical Centers
- Specialized Clinics
By Technology
- Open Surgery
- Endovascular Surgery
By Distribution Channel
- Direct Sales
- Distributors
By Geography
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Spain, Italy, Rest of Europe)
- Asia-Pacific (China, India, Japan, Australia, Vietnam, Rest of APAC)
- The Middle East and Africa (Middle East, Africa)
- South and Central America (Brazil, Argentina, Rest of SCA)
Medtronic, Cook Medical, Terumo Aortic, W. L. Gore & Associates, Endologix, Boston Scientific, Abbott Laboratories, Cardinal Health, CryoLife, MicroPort Scientific, JOTEC GmbH, Lombard Medical, B. Braun Melsungen, Getinge AB, Artivion Inc.
April 2025 – Gore received FDA approval for four new large‑diameter tapered sizes of its TAG Conformable Thoracic Stent Graft with Active Control system, followed by the first U.S. commercial implant, extending applicability in thoracic aneurysm treatment.
January 2025 – Bentley InnoMed launched two products for fenestrated EVAR: the BeGraft on-label bridging stent graft and the first dedicated BeFlared fenestrated bridging system, now commercially available in Europe.
June 2025 – Mayo Clinic reported using physician-modified endografts (PMEG) for complex thoracoabdominal aneurysm repair in clinical cases, highlighting demand for customizable off-the-shelf alternatives when FDA‑approved options are limited.
June 2025 – Nectero Medical received FDA IND clearance to begin its stAAAble Phase II/III pivotal trial evaluating its Nectero EAST® system—a non‑implant approach using pentagalloyl glucose infusion to stabilize growth in small-to-mid‑size infrarenal AAAs.
June 2025 – NYU Langone Vascular Center reported early experience with Cook’s branched and fenestrated stent graft systems—including the Medtronic Valiant™ Manifold device—used in thoraco‑abdominal aneurysm cases to improve outcomes in complex anatomies.
The Aortic Aneurysm Market is estimated to generate $ 5.47 billion in revenue in 2026.
The Aortic Aneurysm Market is expected to grow at a Compound Annual Growth Rate (CAGR) of 10.21% during the forecast period from 2026 to 2034.
The Aortic Aneurysm Market is estimated to reach $ 11.90 billion by 2034.
Didn’t find what you’re looking for? TALK TO OUR ANALYST TEAM
Need something within your budget? NO WORRIES! WE GOT YOU COVERED!